AZN ▼ -0.8% - AstraZeneca PLC $AZN AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer AstraZeneca completed a global license agreement for its oral EGFR inhibitor ZEGFROVY (sunvozertinib) to treat lung cancer, a development that typically expands the drug's commercial reach and potential revenue streams. The stock declined 0.8% today, suggesting investors may have focused on deal terms or timing rather than viewing the licensing completion as an immediate positive catalyst. 01-SEP-2026 07:00 AM ET